Rezolute's stock plunges 87% after hypoglycemia drug flunks pivotal phase 3 test
Rezolute's stock plunges 87% after hypoglycemia drug flunks pivotal phase 3 test
Contenido no disponible. Consulta la fuente original.
Rezolute's stock plunges 87% after hypoglycemia drug flunks pivotal phase 3 test
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.